Rising Purity Expectations Are Reshaping the Chromatography Resin Market

Downstream purification long has been the economic fulcrum of biologics manufacturing, accounting for a significant portion (sometimes up to 80%) of total production costs. Downstream burdens intensify as upstream productivity rises and biologic molecules increase in complexity. Here, chromatography resins are taking center stage by defining process efficiency, manufacturing economics, and ultimately product purity.

The global market for these resins is anticipated to strengthen and grow steadily, reflecting a set of targeted shifts in chromatographic chemistry, technique selection, and performance expectations that mirror broader changes in biopharmaceutical manufacturing.

Defining Today’s Purification Strategies

As downstream processes are pushed to deliver drug substances of ever-higher purity without inflating manufacturing costs, technique selection becomes critical. A chromatography process must provide sufficient specificity to isolate biologics from complex feed streams. 

Affinity chromatography continues to be the biopharmaceutical industry’s method of choice for protein purification, supporting well over two-thirds of such operations. By leveraging highly selective biological interactions, such as those based on protein A resins, affinity chromatography enables efficient capture of monoclonal antibodies (mAbs) and other recombinant proteins with relatively few steps, high yields, and consistently high product quality.

For polishing steps, mixed-mode resins are gaining traction gradually. Although their total demand remains significantly lower than that of traditional ion-exchange resins, mixed-mode offerings are posting a higher growth rate. However, it will take considerable time for mixed-mode options to approach the level of demand for ion-exchange resins, which are expected to remain the second-most used type for the foreseeable future. 

Synthetic or Natural Materials?

Base matrices for chromatography resins can be classified as natural (e.g., based on agarose, cellulose, and dextran), synthetic (polystyrene and polymethacrylate), and inorganic (ceramic hydroxyapatite, CHT). Synthetic options offer comparatively high mechanical stability, chemical resistance, and reusability. Thus, they are effective in industrial-scale and high-pressure applications. Natural resins provide superior biocompatibility and low incidence of nonspecific binding, making them useful for purification of delicate biomolecules. Meanwhile, inorganic resins are based on rigid mineral supports such as bonded/glass silica, aluminum oxide, carbon, and magnesium-silicate gel. Such materials offer high mechanical strength and pressure tolerance, but lower biocompatibility limits their use primarily to high-performance analytical applications and specialized industrial separations.

Natural resins, especially agarose-based affinity resins, continue to anchor large-scale purification workflows due to their biocompatibility, proven regulatory track record, and predictable performance in antibody/protein capture. Over 60% of original equipment manufacturers (OEMs) continue to prefer natural resins, including agarose-based matrices, over fully synthetic polymer resins for chromatography applications.

Several resin products launched in 2025. Among the new protein A–based offerings were Ecolab’s Purolite Jetted A50 HipH and Cytiva’s MabSelect SuRe 70 and MabSelect PrismA X resins, all of which are based on cross-linked agarose. DuPont also released an agarose-based resin: the AmberChrom TQ1 ion exchanger for peptide and oligonucleotide purification. Such releases highlight how suppliers are enhancing natural resin platforms with improved functional chemistries that support high throughput and increasingly complex biopharmaceutical separations.

That said, synthetic resins are achieving measurable gains. Polystyrene- and methacrylate-based materials increasingly are adopted in high-flow, high-pressure environments and in continuous-chromatography setups, where mechanical strength and chemical stability are critical. Uptake for synthetic resins is strongest for intensified processes and purification of next-generation biologics, complementing rather than displacing agarose base matrices. 

Why Pharmaceuticals Generally Drive Resin Demand

Chromatography resins are used frequently in biotechnology laboratories, academic research institutions, chemical processing plants, government research facilities, hospitals, and clinical-trial manufacturing, as well as in agriculture and food and beverage analysis. In each of those settings, resins enable separation and purification of compounds that otherwise would be difficult to isolate with precision. However, the pharmaceutical industry accounts for nearly one-quarter of global resin consumption because chromatography is fundamentally rooted in the industry’s need for highly efficient and selective separation processes across all stages of drug development and manufacturing.

That is particularly true for the biopharmaceutical sector, encompassing mAbs, vaccines, viral-vector gene therapies, and more. All those modalities rely heavily on chromatography resins for isolating target biomolecules from complex solutions and removing process-related impurities such as host-cell proteins and product aggregates. 

In the broader pharmaceutical industry, resins are used frequently to purify active pharmaceutical ingredients (APIs), helping to remove trace solvents, heavy metals, and unreacted intermediates to meet purity requirements — often exceeding 99.9% — for regulatory compliance. Furthermore, controlled-release encapsulation systems that regulate how medication is released in circulation also are supported by specialized resins. 

Regulatory oversight is reinforcing resin adoption. Agencies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) require high-quality products with minimal risk of leaching or contamination. 

All of the above factors ensure sustainable growth in demand for specialized chromatography resins.

What’s Next for Resins as Biologic Purity Standards Tighten?

The biopharmaceutical industry is addressing increasingly stringent purity standards by accelerating adoption of continuous and intensified purification strategies. Suppliers also are devising ways to integrate digital process monitoring with chromatography performance. Such shifts are strengthening demand for resins with extended lifetimes and high binding capacities. The inevitable rise in demand for biosimilars will lift demand further still.

At the same time, challenges persist. Chromatography costs continue to rise, with protein A resins now priced at US$9000–12,000/L. Supply-chain constraints, high-cost raw-material inputs, and stringent validation requirements collectively are increasing resin procurement costs and extending lead times along the biopharmaceutical value chain.

Another key challenge is that chromatography generates solvent waste, which poses environmental and regulatory risks if not properly managed. Although concerns around resin reuse and waste management are gaining attention, practical solutions remain limited. Thus, reduced solvent use remains a central sustainability lever in the pharmaceutical industry, along with adoption of greener solvents. In that regard, uptake is accelerating, with alternatives such as ethanol and techniques such as supercritical fluid chromatography (SFC) using supercritical CO₂ emerging to minimize reliance on toxic solvents. 

Despite cost and operational challenges, continued innovation — particularly in resins designed for gene-therapy vectors and nucleic-acid payloads — is reinforcing the market’s long-term growth as the biopharmaceutical industry moves beyond traditional protein purification. The global chromatography-resins market stood at $2.4 billion in 2020. Within five years, it added >30% in value, and it is expected to maintain that surge and surpass $3.5 billion by 2031.